NASDAQ · CELC
Healthcare · Biotechnology
$69.72
Down-$0.68 (-0.98%)
Updated Nov 4, 2026, 6:57 PM
SID Score
4.2/10
Composite research score
Smart Money
58/100
Neutral
Price performance · CELC
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
CELC closed at $69.72 after 21 trading sessions, down 2.15% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $67.13 | $70.99 | $67.0001 | $69.72 | 1.13M |
| Nov 2, 2026 | $69.50 | $70.1299 | $66.14 | $67.07 | 775.82K |
| Oct 30, 2026 | $68.47 | $70.425 | $67.42 | $69.13 | 700.08K |
| Oct 29, 2026 | $70.66 | $73.285 | $69.00 | $69.30 | 820.62K |
| Oct 28, 2026 | $67.41 | $69.95 | $67.39 | $69.46 | 1.14M |
| Oct 27, 2026 | $66.08 | $68.82 | $65.69 | $68.07 | 885.83K |
| Oct 26, 2026 | $65.50 | $68.39 | $64.9156 | $65.80 | 1.87M |
| Oct 23, 2026 | $65.57 | $66.30 | $63.49 | $65.25 | 1.32M |
| Oct 22, 2026 | $61.74 | $66.93 | $61.74 | $65.57 | 1.93M |
| Oct 21, 2026 | $60.42 | $62.8375 | $60.15 | $61.56 | 1.59M |
| Oct 20, 2026 | $57.12 | $62.56 | $56.81 | $60.00 | 2.38M |
| Oct 19, 2026 | $58.19 | $59.49 | $56.60 | $57.12 | 2.67M |
| Oct 16, 2026 | $60.16 | $60.23 | $53.54 | $56.58 | 4.34M |
| Oct 15, 2026 | $60.67 | $61.73 | $60.00 | $60.30 | 2.12M |
| Oct 14, 2026 | $62.60 | $63.4442 | $58.98 | $59.90 | 2.44M |
| Oct 13, 2026 | $65.17 | $65.69 | $62.86 | $63.19 | 1.5M |
| Oct 12, 2026 | $67.40 | $67.52 | $65.03 | $65.85 | 1.05M |
| Oct 9, 2026 | $67.78 | $68.53 | $66.91 | $67.94 | 1.28M |
| Oct 8, 2026 | $64.735 | $69.08 | $63.225 | $67.87 | 2.59M |
| Oct 7, 2026 | $70.52 | $73.505 | $64.15 | $65.78 | 3.16M |
| Oct 6, 2026 | $74.28 | $76.29 | $70.315 | $71.25 | 1.56M |
The latest Smart Investors Daily articles mentioning CELC.
Company
Market Activity
Research & News
CELC research
Company profile and research snapshot.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 22, 2026 | Cantor Fitzgerald | Overweight | — |
| Oct 21, 2026 | TD Cowen | Buy | — |
| Sep 30, 2026 | Needham | Buy | — |
| Sep 17, 2026 | JP Morgan | Overweight | — |
| Aug 17, 2026 | Citizens | Market Outperform | — |
No generated briefing is available yet.
SeekingAlpha · Oct 30, 2026
Celcuity Inc. retains a Buy rating after REVTORPYK's FDA approval and robust mutant data, despite a significant share price drop. Learn more about CELC stock here.
Yahoo · Oct 29, 2026
MINNEAPOLIS, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that it will release its financial results for the third quarter 2026 after the market closes on Thursday, November 5, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Standard Time to discuss the results and prov
Yahoo · Oct 25, 2026
Celcuity reported past Phase 3 and Phase 1b/2 data at ESMO 2026 showing that gedatolisib regimens improved progression-free outcomes and had manageable safety in advanced breast and prostate cancer settings. The company now has aligned evidence that a single asset, gedatolisib, could address two large hormone-driven tumor types using combination regimens with differentiated tolerability profiles. The focus now shifts to how Celcuity's investment narrative evolves as these VIKTORIA 1 subgroup...
Yahoo · Oct 24, 2026
Median PFS was 21.5 months with the gedatolisib triplet and 11.5 months with the gedatolisib doublet versus 9.1 months with alpelisib + fulvestrant in patients who had no liver metastases ORR and median duration of response was 59% and 19.4 months for the gedatolisib triplet and 43% and 27.8 months for the gedatolisib doublet, respectively, compared to 33% and 7.5 months for alpelisib + fulvestrant The discontinuation rate for gedatolisib due to treatment-emergent adverse events was 5% and 4% wi
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CELC.
